Obalon Therapeutics (Obalon Therapeutics) Days Sales Outstanding : 0.00 (As of Mar. 2021)

View and export this data going back to 2016. Start your Free Trial

What is Obalon Therapeutics Days Sales Outstanding?

Obalon Therapeutics's average Accounts Receivable for the three months ended in Mar. 2021 was $0.00 Mil. Obalon Therapeutics's Revenue for the three months ended in Mar. 2021 was $0.00 Mil.

The historical rank and industry rank for Obalon Therapeutics's Days Sales Outstanding or its related term are showing as below:

OBLN's Days Sales Outstanding is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 64.66
* Ranked among companies with meaningful Days Sales Outstanding only.

Obalon Therapeutics's Days Sales Outstanding declined from Mar. 2020 (43.64) to Mar. 2021 (0.00).

Obalon Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Obalon Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Obalon Therapeutics Days Sales Outstanding Chart

Obalon Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Days Sales Outstanding

Get a 7-Day Free Trial

2.69

155.48

102.13

64.24

65.51

Obalon Therapeutics Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Days Sales Outstanding	Get a 7-Day Free Trial															43.64	59.84	-	-	-

Competitive Comparison of Obalon Therapeutics's Days Sales Outstanding

For the Medical Devices subindustry, Obalon Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Obalon Therapeutics's Days Sales Outstanding Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Obalon Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Obalon Therapeutics's Days Sales Outstanding falls into.

Obalon Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Obalon Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2020 is calculated as

	Days Sales Outstanding (A: Dec. 2020 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2019 )	+	Accounts Receivable (A: Dec. 2020 ))	/	count )	/	Revenue (A: Dec. 2020 )	*	Days in Period
=	( (0.285	+	0)	/	1 )	/	1.588	*	365
=	0.285					/	1.588	*	365
=	65.51

Obalon Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2021 is calculated as:

	Days Sales Outstanding (Q: Mar. 2021 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2020 )	+	Accounts Receivable (A: Mar. 2021 ))	/	count )	/	Revenue (A: Mar. 2021 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Obalon Therapeutics (NAS:OBLN) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Obalon Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Obalon Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Obalon Therapeutics (Obalon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Obalon Therapeutics Inc (NAS:OBLN) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

5421 Avenida Encinas, Suite F, Carlsbad, CA, USA, 92008

Website

https://www.obalon.com

Obalon Therapeutics Inc is a medical device company that focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. Its product includes Obalon Balloon System. Geographically, it derives all of its revenue from the United States.

Executives

Raymond V Dittamore	director	P O BOX 2050, GLENWOOD SPRINGS CO 81602
William J. Plovanic	director	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Sharon Stevenson	director	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ECINAS, SUITE F, CARLSBAD CA 92008
Douglas Fisher	director	587 PATROL RD, WOODSIDE CA 94062
Lesley H Howe	director
Kim P. Kamdar	director	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Andrew P Rasdal	director, officer: President, CEO & Exec Chairman	C/O DEXCOM, INC., 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Nooshin Hussainy	officer: Chief Financial Officer	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Mark Brister	officer: Chief Technology Officer	C/O DEXCOM, INC., 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Robert J Macdonald	officer: Chief Retail Officer	C/O OBALON THERAPEUTICS INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Amy Vandenberg	officer: Chief Clinical & Reg Officer	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Nicole Vitullo	10 percent owner	3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Brian H Dovey	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Arnold L Oronsky	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Gilbert H Kliman	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022